Clinical progress is correspondingly trivial with respect to pharmaceutical therapies (particularly NASH, a key contributor to hepatocellular carcinoma, HCC), while managing metabolic causes of this condition (e.g., by targeting miRNAs, GLP-1, PPARs) is in the early stages [50]. This evidence concerns the gene GCG and hepatocellular carcinoma.